Program
H5 Flu IMP 2
Also written as “H5 Flu IMP 3”, “H5 Flu IMP 7” and “H5 Flu IMP 8”.
Its studies are mostly in Respiratory Syncytial Virus Infections, led by Sanofi.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Sanofi | 11 open or running | phase 1since Mar 31, 2026 | Mar 31, 2026 | Apr 4, 2027phase 1 · NCT07516418 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Mar 31, 2026First study: phase 1 study in Respiratory Syncytial Virus InfectionsFirst studyNCT07516418 · 360 enrolled · Australia
Ahead
- Apr 4, 2027Primary completion: phase 1 study in Respiratory Syncytial Virus InfectionsNCT07516418
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07516418Respiratory Syncytial Virus Infections · Australia | 1 | Active, not recruiting | Apr 4, 2027 | 360 |
How it is read
Names in the registry
- “H5 Flu IMP 2”, 1 entry
- “H5 Flu IMP 3”, 1 entry
- “H5 Flu IMP 7”, 1 entry
- “H5 Flu IMP 8”, 1 entry
- “H5 Flu IMP 9”, 1 entry
Conditions, from the studies’ own filings
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.